146 related articles for article (PubMed ID: 26946633)
21. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
22. [Cervical HPV infection; epidemiology and vaccination].
Yoshikawa H
Kansenshogaku Zasshi; 2008 Nov; 82(6):609-12. PubMed ID: 19086414
[No Abstract] [Full Text] [Related]
23. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
Schiffman M
Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
[TBL] [Abstract][Full Text] [Related]
24. NIH lab helps get vaccine from bench to bedside.
Traynor K
Am J Health Syst Pharm; 2007 Mar; 64(5):452. PubMed ID: 17322152
[No Abstract] [Full Text] [Related]
25. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil): profile report.
Siddiqui MA; Perry CM
BioDrugs; 2006; 20(5):313-6. PubMed ID: 17025377
[No Abstract] [Full Text] [Related]
26. Screening for cervical cancer: controversy and contention or thoughtful analysis.
Frable WJ
Cancer; 2007 Jun; 111(3):143-4. PubMed ID: 17487849
[No Abstract] [Full Text] [Related]
27. Cervical cancer vaccine development.
Frazer IH
Sex Health; 2010 Sep; 7(3):230-4. PubMed ID: 20719210
[TBL] [Abstract][Full Text] [Related]
28. No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus.
Pellegrino P; Carnovale C; Perrone V; Antoniazzi S; Pozzi M; Clementi E; Radice S
Eur J Epidemiol; 2013 Aug; 28(8):705-7. PubMed ID: 23864234
[No Abstract] [Full Text] [Related]
29. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
30. [HPV immunization for the prevention of cervical cancer].
Mougin C; Bourgault-Villada I; Coursaget P
Presse Med; 2009 Dec; 38(12):1750-68. PubMed ID: 19765945
[TBL] [Abstract][Full Text] [Related]
31. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
32. HPV vaccination: too soon for 2 doses?
Kahn JA; Bernstein DI
JAMA; 2013 May; 309(17):1832-4. PubMed ID: 23632729
[No Abstract] [Full Text] [Related]
33. Prevention of cervical cancer through vaccination of adolescents.
Pichichero ME
Clin Pediatr (Phila); 2006 Jun; 45(5):393-8. PubMed ID: 16891270
[No Abstract] [Full Text] [Related]
34. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.
Baussano I; Lazzarato F; Ronco G; Dillner J; Franceschi S
Int J Cancer; 2013 Oct; 133(8):1876-81. PubMed ID: 23564420
[TBL] [Abstract][Full Text] [Related]
35. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
36. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
Szarewski A
Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
[TBL] [Abstract][Full Text] [Related]
37. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
38. The impact of an imperfect vaccine and pap cytology screening on the transmission of human papillomavirus and occurrence of associated cervical dysplasia and cancer.
Malik T; Reimer J; Gumel A; Elbasha EH; Mahmud S
Math Biosci Eng; 2013 Aug; 10(4):1173-205. PubMed ID: 23906207
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.
Heijstek MW; Scherpenisse M; Groot N; Tacke C; Schepp RM; Buisman AM; Berbers GA; van der Klis FR; Wulffraat NM
Ann Rheum Dis; 2014 Aug; 73(8):1500-7. PubMed ID: 23723319
[TBL] [Abstract][Full Text] [Related]
40. Gardasil: Introducing the new human papillomavirus vaccine.
McLemore MR
Clin J Oncol Nurs; 2006 Oct; 10(5):559-60. PubMed ID: 17063609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
